Conor MacKay
Stock Analyst at BMO Capital
(0.81)
# 4,060
Out of 4,994 analysts
7
Total ratings
20%
Success rate
-12.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Conor MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Maintained: Buy | $58 | $22.58 | +156.86% | 3 | Sep 22, 2026 | |
| INSM Insmed | Reiterated: Buy | $192 | $121.00 | +58.68% | 3 | Aug 17, 2026 | |
| TRVI Trevi Therapeutics | Initiated Coverage: Buy | $36 | $14.89 | +141.77% | 1 | Jul 21, 2026 |
NewAmsterdam Pharma Company
Sep 22, 2026
Maintained: Buy
Price Target: $58
Current: $22.58
Upside: +156.86%
Insmed
Aug 17, 2026
Reiterated: Buy
Price Target: $192
Current: $121.00
Upside: +58.68%
Trevi Therapeutics
Jul 21, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $14.89
Upside: +141.77%